JP2018519323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519323A5 JP2018519323A5 JP2017568177A JP2017568177A JP2018519323A5 JP 2018519323 A5 JP2018519323 A5 JP 2018519323A5 JP 2017568177 A JP2017568177 A JP 2017568177A JP 2017568177 A JP2017568177 A JP 2017568177A JP 2018519323 A5 JP2018519323 A5 JP 2018519323A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- fluorine
- represents hydrogen
- group
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000001257 hydrogen Substances 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 16
- 229910052731 fluorine Inorganic materials 0.000 claims 15
- 239000011737 fluorine Chemical group 0.000 claims 15
- 150000002431 hydrogen Chemical class 0.000 claims 15
- 239000012453 solvate Substances 0.000 claims 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 11
- -1 hydroxy, methyl Chemical group 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 229910052801 chlorine Inorganic materials 0.000 claims 8
- 239000000460 chlorine Substances 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 6
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000001425 triazolyl group Chemical group 0.000 claims 4
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 230000009424 thromboembolic effect Effects 0.000 claims 3
- 230000001732 thrombotic effect Effects 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 claims 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 238000006069 Suzuki reaction reaction Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15176099.8 | 2015-07-09 | ||
| EP15176099 | 2015-07-09 | ||
| EP16157350 | 2016-02-25 | ||
| EP16157350.6 | 2016-02-25 | ||
| PCT/EP2016/065787 WO2017005725A1 (en) | 2015-07-09 | 2016-07-05 | Substituted oxopyridine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519323A JP2018519323A (ja) | 2018-07-19 |
| JP2018519323A5 true JP2018519323A5 (enExample) | 2019-08-15 |
| JP6871180B2 JP6871180B2 (ja) | 2021-05-12 |
Family
ID=56345141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568177A Active JP6871180B2 (ja) | 2015-07-09 | 2016-07-05 | 置換オキソピリジン誘導体 |
Country Status (39)
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016046158A1 (de) * | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| CA2979937A1 (en) * | 2015-03-19 | 2016-09-22 | Bayer Pharma Aktiengesellschaft | Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis |
| JO3703B1 (ar) * | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| CN113912586B (zh) | 2016-08-31 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 |
| KR102807521B1 (ko) * | 2018-03-15 | 2025-05-16 | 바이엘 악티엔게젤샤프트 | 2종의 4-｛[(2s)-2-｛4-[5-클로로-2-(1h-1,2,3-트리아졸-1-일)페닐]-5-메톡시-2-옥소피리딘-1(2h)-일}부타노일]아미노}-2-플루오로벤즈아미드 유도체의 제조 방법 |
| DK3774796T3 (da) | 2018-04-10 | 2022-07-18 | Bayer Pharma AG | Et substitueret oxopyridinderivat |
| WO2020007256A1 (zh) | 2018-07-02 | 2020-01-09 | 江苏恒瑞医药股份有限公司 | 一种氧代吡啶酰胺类衍生物的晶型及制备方法 |
| AR115870A1 (es) | 2018-07-31 | 2021-03-10 | Sumitomo Chemical Co | MÉTODO PARA CONTROLAR EL HONGO DE LA ROYA DE LA SOJA QUE TIENE RESISTENCIA AL INHIBIDOR DE SITIO Qₒ |
| WO2020126682A1 (en) | 2018-12-17 | 2020-06-25 | Bayer Aktiengesellschaft | Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications |
| WO2020127508A1 (en) | 2018-12-21 | 2020-06-25 | Bayer Aktiengesellschaft | Substituted oxopyridine derivatives |
| EA202191764A1 (ru) | 2018-12-21 | 2021-10-22 | Байер Акциенгезельшафт | Замещенные оксопиридиновые производные |
| EP4036087A4 (en) | 2019-09-27 | 2023-09-20 | Shenzhen Salubris Pharmaceuticals Co. Ltd | FXA INHIBITORS AND METHODS OF PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF |
| WO2022057849A1 (zh) | 2020-09-17 | 2022-03-24 | 浙江海正药业股份有限公司 | 哌嗪类衍生物及其制备方法和用途 |
| CN114621140B (zh) * | 2020-12-10 | 2023-08-11 | 中国科学院上海药物研究所 | 芳基二氟乙酰胺化合物及其制备方法和用途 |
| MX2023010614A (es) * | 2021-03-09 | 2023-09-19 | Bayer Ag | Formas cristalinas de (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?, 5-dioxo-14-(trifluoro-metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2, 3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida. |
| GEAP202316370A (en) * | 2021-03-09 | 2023-11-27 | Bayer Ag | Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3] triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide |
| WO2022189280A1 (en) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| US11919881B2 (en) | 2021-03-18 | 2024-03-05 | Janssen Pharmaceutica Nv | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| US11814364B2 (en) | 2021-03-18 | 2023-11-14 | Janssen Pharmaceutica Nv | Pyridine N-oxide derivatives useful as factor XIa inhibitors |
| US11845748B2 (en) | 2021-03-18 | 2023-12-19 | Janssen Pharmaceutica Nv | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| CN113666826B (zh) * | 2021-07-30 | 2024-03-26 | 五邑大学 | 一种芳基或杂芳基甲氧基化反应的方法 |
| CN116199672A (zh) * | 2021-11-30 | 2023-06-02 | 成都泰和伟业生物科技有限公司 | 一种嘧啶酰胺类衍生物及其制备方法和用途 |
| WO2023174399A1 (zh) * | 2022-03-18 | 2023-09-21 | 苏州晶云药物科技股份有限公司 | 取代的氧代吡啶类衍生物的晶型及其制备方法 |
| CN116262735B (zh) * | 2022-11-18 | 2025-05-13 | 成都施贝康生物医药科技有限公司 | 新型氧代吡啶类化合物及其制备方法和用途 |
| CN116262734B (zh) * | 2022-11-18 | 2025-05-13 | 成都施贝康生物医药科技有限公司 | 氧代吡啶类化合物及其制备方法和用途 |
| CN116262740A (zh) * | 2022-11-18 | 2023-06-16 | 成都施贝康生物医药科技有限公司 | 新型氧代吡啶类化合物及其制备方法和用途 |
| CN116082303B (zh) * | 2022-12-21 | 2025-02-25 | 成都施贝康生物医药科技有限公司 | 新型氧代吡啶类化合物及其中间体和应用 |
| CN116262736B (zh) * | 2022-12-26 | 2025-05-13 | 成都施贝康生物医药科技有限公司 | 新型氧代吡啶类化合物及其制备方法和用途 |
| JP2026509613A (ja) | 2023-03-31 | 2026-03-19 | バイエル・アクチエンゲゼルシヤフト | （４ｓ）－２４－クロロ－４－エチル－７３－フルオロ－３５－メトキシ－３２，５－ジオキソ－１４－（トリフルオロメチル）－３２ｈ－６－アザ－３（４，１）－ピリジナ－１（１）－［１，２，３］トリアゾラ－２（１，２），７（１）－ジベンゼナヘプタファン－７４－カルボキサミドを含む医薬剤形 |
| CN116621728B (zh) * | 2023-06-09 | 2025-07-29 | 成都施贝康生物医药科技有限公司 | 氧代吡啶类化合物的新型制备方法及关键中间体 |
| CN116535392B (zh) * | 2023-06-26 | 2023-09-05 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物的制备方法及中间体和应用 |
| CN116751136B (zh) * | 2023-06-21 | 2025-08-29 | 成都施贝康生物医药科技有限公司 | 氧代吡啶类化合物的新型制备方法及关键中间体 |
| JP2026524091A (ja) | 2023-06-09 | 2026-07-17 | チォンドウ シーベイカン バイオメディカル テクノロジー カンパニー リミテッド | オキソピリジン系化合物の新規製造方法及びキー中間体と応用 |
| CN116621742B (zh) * | 2023-06-09 | 2025-05-06 | 成都施贝康生物医药科技有限公司 | 氧代吡啶类化合物的新型制备方法及关键中间体 |
| CN116730861A (zh) * | 2023-06-21 | 2023-09-12 | 成都施贝康生物医药科技有限公司 | 氧代吡啶类化合物的新型制备方法及关键中间体 |
| CN116874387B (zh) * | 2023-06-21 | 2025-08-26 | 成都施贝康生物医药科技有限公司 | 氧代吡啶类化合物的新型制备方法及关键中间体 |
| TW202515882A (zh) | 2023-06-30 | 2025-04-16 | 大陸商深圳信立泰藥業股份有限公司 | 一種多取代的大環化合物及其製備方法與應用 |
| CN117164562B (zh) * | 2023-09-07 | 2025-06-13 | 成都施贝康生物医药科技有限公司 | 一种氧代哒嗪类化合物及其制备方法和用途 |
| CN117164565B (zh) * | 2023-09-07 | 2025-05-27 | 成都施贝康生物医药科技有限公司 | 一种氧代嘧啶类化合物及其制备方法和用途 |
| CN117164564B (zh) * | 2023-09-07 | 2025-07-08 | 成都施贝康生物医药科技有限公司 | 氧代哒嗪类化合物及其制备方法和用途 |
| CN117164561A (zh) * | 2023-09-07 | 2023-12-05 | 成都施贝康生物医药科技有限公司 | 一种氧代嘧啶类化合物及其制备方法和用途 |
| CN117164563B (zh) * | 2023-09-07 | 2025-06-10 | 成都施贝康生物医药科技有限公司 | 氧代嘧啶类化合物及其制备方法和用途 |
| CN117164566B (zh) * | 2023-09-07 | 2025-06-06 | 成都施贝康生物医药科技有限公司 | 一种氧代哒嗪类化合物及其制备方法和用途 |
| CN117186073B (zh) * | 2023-09-08 | 2025-06-06 | 成都施贝康生物医药科技有限公司 | 氧代嘧啶类化合物及其制备方法和用途 |
| CN118894814B (zh) * | 2024-07-15 | 2025-09-12 | 上海康鹏科技股份有限公司 | 1-(2-溴-4-氯苯基)-4-(三氟甲基)-1h-1，2，3-三唑的制备方法 |
| WO2026119653A1 (en) | 2024-12-02 | 2026-06-11 | Bayer Aktiengesellschaft | Preparative process |
| WO2026119652A1 (en) | 2024-12-02 | 2026-06-11 | Bayer Aktiengesellschaft | Preparative process |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
| EP1332131A2 (en) | 2000-11-07 | 2003-08-06 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
| EP1526131A1 (en) | 2003-10-22 | 2005-04-27 | Graffinity Pharmaceuticals Aktiengesellschaft | Aminoalkyl-pyrazinones and -pyridones as thrombin inhibitors |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| EP2016072B1 (en) | 2006-05-05 | 2014-07-16 | Millennium Pharmaceuticals, Inc. | Factor xa inhibitors |
| JP5419706B2 (ja) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| UA103918C2 (en) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| IN2014CN02805A (enExample) | 2011-10-14 | 2015-07-03 | Bristol Myers Squibb Co | |
| GB2497806A (en) | 2011-12-21 | 2013-06-26 | Ono Pharmaceutical Co | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors |
| WO2013093484A1 (en) | 2011-12-21 | 2013-06-27 | Ono Pharmaceutical Co., Ltd. | Pyridinone and pyrimidinone derivatives as factor xia inhibitors |
| KR20150038372A (ko) * | 2012-08-03 | 2015-04-08 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 XIa 억제제로서의 디히드로피리돈 P1 |
| EP2968207A4 (en) | 2013-03-14 | 2016-09-28 | Chdi Foundation Inc | HISTON DEACETYLASE INHIBITORS AND COMPOSITIONS |
| US9809545B2 (en) | 2013-03-27 | 2017-11-07 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| TWI633089B (zh) | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| US9475809B2 (en) | 2013-07-23 | 2016-10-25 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof as factor xia/plasma |
| WO2015063093A1 (de) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| JP6505727B2 (ja) | 2014-01-31 | 2019-04-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| WO2015120777A1 (zh) * | 2014-02-14 | 2015-08-20 | 四川海思科制药有限公司 | 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用 |
| WO2016046158A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| WO2016046166A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| JP6517925B2 (ja) | 2014-09-24 | 2019-05-22 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたオキソピリジン誘導体 |
| ES2716417T3 (es) | 2014-09-24 | 2019-06-12 | Bayer Pharma AG | Derivados de oxopiridina sustituidos con acción antiinflamatoria y antitrombótica |
| WO2016046156A1 (de) * | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| ES2712886T3 (es) | 2014-09-24 | 2019-05-16 | Bayer Pharma AG | Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa |
| JO3703B1 (ar) * | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| US10336730B2 (en) * | 2015-08-05 | 2019-07-02 | Bristol-Myers Squibb Company | Substituted glycine derived FXIA inhibitors |
-
2016
- 2016-07-03 JO JOP/2016/0136A patent/JO3703B1/ar active
- 2016-07-05 KR KR1020187003576A patent/KR102596164B1/ko active Active
- 2016-07-05 JP JP2017568177A patent/JP6871180B2/ja active Active
- 2016-07-05 PL PL16734672T patent/PL3319956T3/pl unknown
- 2016-07-05 PE PE2018000035A patent/PE20180538A1/es unknown
- 2016-07-05 LT LTEP16734672.5T patent/LT3319956T/lt unknown
- 2016-07-05 AU AU2016289746A patent/AU2016289746B2/en active Active
- 2016-07-05 CN CN201680052335.5A patent/CN108026072B/zh active Active
- 2016-07-05 US US15/742,063 patent/US10421742B2/en active Active
- 2016-07-05 EA EA201890111A patent/EA036208B1/ru not_active IP Right Cessation
- 2016-07-05 GE GEAP201914692A patent/GEAP201914692A/en unknown
- 2016-07-05 EP EP16734672.5A patent/EP3319956B1/en active Active
- 2016-07-05 HR HRP20210459TT patent/HRP20210459T1/hr unknown
- 2016-07-05 CU CU2018000001A patent/CU24512B1/es unknown
- 2016-07-05 WO PCT/EP2016/065787 patent/WO2017005725A1/en not_active Ceased
- 2016-07-05 GE GEAP201614692A patent/GEP20197046B/en unknown
- 2016-07-05 MA MA42376A patent/MA42376B1/fr unknown
- 2016-07-05 HU HUE16734672A patent/HUE053552T2/hu unknown
- 2016-07-05 MY MYPI2018700053A patent/MY196640A/en unknown
- 2016-07-05 CN CN202110557164.4A patent/CN113292539B/zh active Active
- 2016-07-05 RS RS20210338A patent/RS61584B1/sr unknown
- 2016-07-05 DK DK16734672.5T patent/DK3319956T3/da active
- 2016-07-05 CR CR20180017A patent/CR20180017A/es unknown
- 2016-07-05 UA UAA201801270A patent/UA122341C2/uk unknown
- 2016-07-05 TN TNP/2018/000011A patent/TN2018000011A1/en unknown
- 2016-07-05 SI SI201631060T patent/SI3319956T1/sl unknown
- 2016-07-05 MX MX2018000076A patent/MX377903B/es unknown
- 2016-07-05 ES ES16734672T patent/ES2856554T3/es active Active
- 2016-07-05 CA CA2990901A patent/CA2990901C/en active Active
- 2016-07-07 TW TW105121492A patent/TWI717367B/zh active
- 2016-07-08 UY UY0001036780A patent/UY36780A/es active IP Right Grant
-
2017
- 2017-12-25 IL IL256556A patent/IL256556B/en active IP Right Grant
-
2018
- 2018-01-04 NI NI201800001A patent/NI201800001A/es unknown
- 2018-01-05 PH PH12018500057A patent/PH12018500057A1/en unknown
- 2018-01-05 CL CL2018000039A patent/CL2018000039A1/es unknown
- 2018-01-05 DO DO2018000004A patent/DOP2018000004A/es unknown
- 2018-01-08 SV SV2018005610A patent/SV2018005610A/es unknown
- 2018-01-08 EC ECIEPI20181308A patent/ECSP18001308A/es unknown
- 2018-01-09 CO CONC2018/0000113A patent/CO2018000113A2/es unknown
- 2018-02-08 ZA ZA2018/00826A patent/ZA201800826B/en unknown
-
2019
- 2019-08-08 US US16/535,120 patent/US11180471B2/en active Active
-
2021
- 2021-03-26 CY CY20211100269T patent/CY1123996T1/el unknown
- 2021-10-18 US US17/504,243 patent/US20230024752A1/en not_active Abandoned
-
2025
- 2025-05-27 US US19/219,838 patent/US20250282748A1/en active Pending